Association between Cannabis Use Disorder and Self- and Other-Directed Aggression

Cannabis is the most widely used drug worldwide. Data about the association of cannabis use with aggression is heterogeneous. The objective of the current study was to assess the nature of the association between cannabis use disorder (CUD) and self-directed, other-directed, and combined aggression. We used data from the National Survey on Drug Use and Health across 2008 to -2014, with a pooled sample of 270,227 adult respondents. We used regression models to estimate the odds ratios (ORs) for those having CUD perpetrating each form of aggression compared with no aggression and other-directed compared with self-directed aggression. CUD was associated with significantly increased odds of committing other-directed (adjusted OR [aOR] = 1.42, 95 percent CI = 1.26-1.60) and combined aggression (aOR = 2.11, 95 percent CI = 1.36-3.26) compared with no aggression. CUD was associated with a nonstatistically significant risk of other-directed compared with self-directed aggression (aOR = 1.29, 95 percent CI = .97-1.69). In those 18 to 25 years old, CUD was significantly associated with an increased differential risk of other-directed versus self-directed aggression (aOR = 1.29, 95 percent CI = 1.03-1.62). Cannabis use disorder seems to increase the risk of other-directed aggression compared with self-directed aggression, especially among youths.

For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.

Visit the IASIC Library here (https://iasic1.org/library/). The IASIC Library is intended as a user-friendly reference of the published medical literature.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Related Posts

IASIC Speaker Series Presents  Cannabis and Mental Health

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Placebo Effect a Major Driver of Pain Reduction in Cannabis Trials

A strong placebo response may be largely responsible for the significant pain reduction observed in clinical trials of cannabis-based therapies, results of a new meta-analysis suggest. Investigators found that while the effect size of cannabinoids on pain intensity was significant, the placebo effect was about the same. “The data from the present meta-analysis, including 1459

Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration, 2005–2019

Since 2005, diagnoses of cannabis use disorder have increased substantially among VHA patients, as they have in the general population and other patient populations. Possible explanations warranting investigation include decreasing perception of risk, changing laws, increasing cannabis potency, stressors related to growing socioeconomic inequality, and use of cannabis to self-treat pain. Clinicians and the public

Cannabis legalization and cannabis-involved pregnancy hospitalizations in Colorado

The primary objective of this study was to evaluate the association between presence of recreational cannabis dispensaries and prevalence of cannabis-involved pregnancy hospitalizations in Colorado. This was a retrospective cohort study of pregnancy-related hospitalizations co-coded with cannabis diagnosis codes in the Colorado Hospital Association from January 1, 2011, through December 31, 2018 (recreational cannabis began

Scroll to Top